We found that the expression of SLC3A2 in cancer tissues is higher than that in normal tissues, and is related to the poor prognosis of cancer patients, which suggests that targeting SLC3A2 may bring clinical benefits in cancer patients. This evidence concerns the gene SLC3A2 and cancer.